Posted by Michael Wonder on 16 Nov 2023
US FDA approves Augtyro (repotrectinib), a next generation tyrosine kinase inhibitor for the treatment of locally advanced or metastatic ROS1 positive non-small-cell lung cancer
15 November 2023 - The approval is based on the pivotal TRIDENT-1 trial, in which Augtyro successfully achieved a high objective response rate and durable response.
Bristol Myers Squibb today announced that the US FDA approved Augtyro(repotrectinib) for the treatment of adult patients with locally advanced or metastatic ROS1 positive non-small-cell lung cancer.
